Maternal RSV vaccine could significantly reduce clinical visits, costs

Pfizer’s maternal vaccine against respiratory syncytial virus could significantly decrease clinical visits among infants and save more than $800 million in overall costs, according to a study presented at IDWeek.
The CDC recommended Pfizer’s RSV vaccine for pregnant people last month after the FDA approved it as a single intramuscular injection given at 32 through 36 weeks’ gestational age.
Amy W. Law, PharmD, director of global value and evidence at Pfizer, and colleagues used a cohort model to study the potential public health impact from birth to age 1 year if 100% of

Pfizer’s maternal vaccine against respiratory syncytial virus could significantly decrease clinical visits among infants and save more than $800 million in overall costs, according to a study presented at IDWeek.
The CDC recommended Pfizer’s RSV vaccine for pregnant people last month after the FDA approved it as a single intramuscular injection given at 32 through 36 weeks’ gestational age.
Amy W. Law, PharmD, director of global value and evidence at Pfizer, and colleagues used a cohort model to study the potential public health impact from birth to age 1 year if 100% of